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PCardiovascular Risk
The Relationship of Left Ventricular Mass
and Geometry to Incident Cardiovascular Events
The MESA (Multi-Ethnic Study of Atherosclerosis) Study
David A. Bluemke, MD, PHD,* Richard A. Kronmal, PHD,† João A. C. Lima, MD,* Kiang Liu, PHD,‡
Jean Olson, MD, MPH,§ Gregory L. Burke, MD, MS, Aaron R. Folsom, MD¶
Baltimore and Bethesda, Maryland; Seattle, Washington; Chicago, Illinois; Winston-Salem, North Carolina;
and Minneapolis, Minnesota
Objective The purpose of this study was to evaluate the relationship of left ventricular (LV) mass and geometry measured
with cardiac magnetic resonance imaging (MRI) to incident cardiovascular events in the MESA (Multi-Ethnic
Study of Atherosclerosis) study.
Background MRI is highly accurate for evaluation of heart size and structure and has not previously been used in a large epi-
demiologic study to predict cardiovascular events.
Methods A total of 5,098 participants in the MESA study underwent cardiac MRI at the baseline examination and were
followed up for a median of 4 years. Cox proportional hazard models were constructed to predict the end points
of coronary heart disease (CHD), stroke, and heart failure (HF) after adjustment for cardiovascular risk factors.
Results A total of 216 incident events were observed during the follow-up period. In adjusted models, the end points of
incident CHD and stroke were positively associated with increased LV mass-to-volume ratio (CHD, hazard ratio
[HR]: 2.1 per g/ml, p  0.02; stroke, HR: 4.2 per g/ml, p  0.005). In contrast, LV mass showed the strongest
association with incident HF events (HR: 1.4 per 10% increment, p  0.0001). The HF events occurred primarily
in participants with LV hypertrophy, that is, 95th percentile of LV mass (HR: 8.6, 95% confidence interval: 3.7
to 19.9, reference group 50th percentile of LV mass).
Conclusions The LV size was related to incident HF, stroke, and CHD in this multiethnic cohort. Whereas body size-adjusted LV
mass alone predicted incident HF, concentric ventricular remodeling predicted incident stroke and CHD. (J Am Coll
Cardiol 2008;52:2148–55) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.09.014w
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che Framingham Study (1–3) and other population-based
tudies (4–7) have shown that increased left ventricular
LV) mass, known as left ventricular hypertrophy (LVH), is
n independent predictor of cardiovascular events in
opulation-based studies using electrocardiograms (ECGs)
r echocardiography to define LVH. The value of LVH to
redict cardiovascular disease events holds for individuals
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ccepted September 4, 2008.ithout (1–3,7) as well as with prior known coronary heart
isease (CHD) (5,8) and heart failure (HF) (9,10). Reduc-
ion of LV mass as a result of therapeutic intervention
educes cardiovascular events (11–14), indicating that LV
ass is an important subclinical marker of cardiovascular
isease (15).
LVH is associated with multiple factors, such as increased
ge, blood pressure, and diabetes (16–19), resulting in
ncreased stiffness of the LV. Geometric changes of the
entricle, termed remodeling, have been investigated pri-
arily by echocardiography in relationship to cardiovascular
vents (20–24). Echocardiographic estimates of LVH, de-
ned by LV diameters and wall thickness normalized by
ody surface area 125 g/m2 (25) and the ratio of posterior
all thickness to LV radius 0.45 (22), have been used to
efine concentric remodeling of the LV. The presence and
attern of ventricular remodeling has been noted to confer
ardiovascular risk beyond LVH in some studies (22,24,26,27),
ut not in others (23,28).
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December 16/23, 2008:2148–55 LV Mass and Geometry Predicting Events in the MESA StudyMagnetic resonance imaging (MRI) is highly accurate
nd reproducible for assessing 3-dimensional ventricular
ize and shape (29–34), and thus may allow additional
nsight into the pathophysiology of myocardial remodeling.
n this study, we report the relationship between LV mass
nd volume as determined by MRI to incident cardiovas-
ular disease in a multiethnic cohort free from clinical
ardiovascular disease at baseline.
ethods
ubjects. The MESA (Multi-Ethnic Study of Atheroscle-
osis) study has been previously described (35). In brief,
etween July 2000 and August 2002, 6,814 men and women
ho identified themselves as white, African-American,
ispanic, or Chinese and were 45 to 84 years old and free
f clinically apparent cardiovascular disease were recruited
rom 6 U.S. communities: Baltimore City and Baltimore
ounty, Maryland; Chicago, Illinois; Forsyth County,
orth Carolina; Los Angeles County, California; Northern
anhattan and the Bronx, New York; and St. Paul,
innesota. Consenting participants underwent a cardiac
RI scan a median of 16 days after the baseline evaluation;
5% were completed by 11 weeks after the baseline exam-
nation. The institutional review boards at all participating
enters approved the study, and all participants gave in-
ormed consent.
isk factor measures. Standardized questionnaires were
sed to obtain information about smoking history and
edication usage for high blood pressure, high cholesterol,
nd diabetes. Smoking was defined as current, former, or
ever. Subjects had their height and weight measured.
esting blood pressure was measured 3 times with partici-
ants in the seated position with a Dinamap model Pro 100
utomated oscillometric sphygmomanometer (Critikon,
E Healthcare, Waukesha, Wisconsin). The average of the
ast 2 measurements was used in analysis. Total and high-
ensity lipoprotein cholesterol and glucose levels were
easured from blood samples obtained after a 12-h fast.
ow-density lipoprotein cholesterol was calculated with the
riedewald equation (36).
Diabetes was defined as fasting glucose 126 mg/dl or
se of hypoglycemic medication. Impaired fasting glucose
as defined as fasting glucose 100 to 125 mg/dl. Hyperten-
ion status was classified according to the Seventh Report of
he Joint National Committee on the Detection, Evalua-
ion, and Treatment of High Blood Pressure (37). Body
ass index (kg/m2) was calculated from weight measured to
he nearest 0.5 kg and height to the nearest 0.1 cm.
ardiac MRI. Cardiac MRI was performed with 1.5-T
agnets with determination of LV mass and volumes as
reviously described (38). Briefly, a stack of short-axis
mages covering the entire LV was acquired with time to
epetition/time to echo 8 to 10 ms/3 to 5 ms, flip angle 20°,
-mm slice thickness, 4-mm gap, flow compensation, in-
lane resolution 1.4 to 1.6 mm (frequency)  2.2 to 2.5 em. The endocardial and epi-
ardial myocardial borders were
ontoured using a semiauto-
ated method (MASS 4.2, Me-
is, Leiden, the Netherlands).
he difference between the epi-
ardial and endocardial areas for
ll slices was multiplied by the
lice thickness and section gap,
nd then multiplied by the spe-
ific gravity of myocardium (1.04
/ml) to determine the ventricu-
ar mass. Papillary muscle mass
as included in the LV cavity
nd excluded from the LV mass.
his approach showed better re-
roducibility than contouring of individual papillary muscles
n preliminary data analyses. A study of repeat measure-
ents of LV mass on 79 MESA study subjects performed
etween 3 and 6 months after the initial measurement
howed the technical error of measurement percent of the
ean was 6% and 4% for LV mass and end-diastolic
olume, respectively, and the intraclass correlation coeffi-
ients were 0.98 and 0.98, respectively (38).
Preliminary evaluation showed that MRI measured LV
ass and volume indexed by body surface area, height2.7, or
eight1.9 did not fully remove the correlation of these
easures with weight and/or height. Using an allometric
pproach (39), regression models for body size were derived
rom a sample of 1,746 MESA study participants without
besity, hypertension, antihypertensive medication use, di-
betes, impaired fasting glucose, or hypoglycemic medica-
ion use using a multiplicative model estimated by regress-
ng log(LV mass) on log(height), log(weight), and sex. The
V mass was adjusted for body size by dividing 100  LV
ass by the predicted LV mass based on height, weight, and
ex, as: 100  LV mass / (a  height0.54  weight0.61),
here a  6.82 for women and 8.25  men with mass in
rams, height in meters, weight in kilograms. Similarly, the
ody size-adjusted LV end-diastolic volume was computed as:
00  LV  volume/(b  height1.25  weight0.43), where
 10.0 for women and 10.5 for men and LV end-diastolic
olume is in milliliters.
djudication of events. Participants were followed up for
ncident cardiovascular events up to 5.2 years from their
aseline examinations. In addition to 3 follow-up MESA
tudy examinations, a telephone interviewer contacted each
articipant every 9 to 12 months to inquire about all interim
ospital admissions, cardiovascular outpatient diagnoses,
nd deaths. To verify self-reported diagnoses, copies were
equested of all death certificates and medical records for all
ospitalizations and outpatient cardiovascular diagnoses.
ext-of-kin interviews for out-of-hospital cardiovascular
eaths were obtained. We were successful in getting medical
ecords on an estimated 98% of hospitalized cardiovascular
Abbreviations
and Acronyms
CHD  coronary heart
disease
CI  confidence interval
ECG  electrocardiogram
HF  heart failure
HR  hazard ratio
LV  left
ventricle/ventricular
LVH  left ventricular
hypertrophy
MRI  magnetic resonance
imagingvents and information on 95% of outpatient cardiovascular
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LV Mass and Geometry Predicting Events in the MESA Study December 16/23, 2008:2148–55iagnostic encounters. Follow-up telephone interviews were
ompleted in 92% of living participants.
Trained personnel abstracted any medical records sug-
esting possible cardiovascular events. Two physicians
rom the MESA study events committee independently
eviewed all medical records for end point classification
nd assignment of incidence dates. The reviewers were
linded to the MESA study MRI results and used
re-specified criteria (see Online Appendix for detailed
riteria for all events). If the reviewing physicians dis-
greed on the event classification, they adjudicated dif-
erences. If disagreements persisted, the full events com-
ittee made the final classification.
Reviewers classified myocardial infarction as definite,
robable, or absent, based primarily on combinations of
ymptoms (e.g., chest pain), ECG abnormalities, and car-
iac biomarker levels (Online Appendix). Coronary heart
isease death was classified as present or absent based on
ospital records and interviews with families. Definite fatal
HD required a myocardial infarction within 28 days of
eath, chest pain within the 72 h before death, or a history
f CHD and the absence of a known nonatherosclerotic or
oncardiac cause of death. Adjudicators graded angina
ased on their clinical judgment as definite, probable, or
bsent. Definite and probable angina required clear docu-
entation of chest pain or anginal equivalent. Definite
ngina also required objective evidence of reversible myo-
ardial ischemia or obstructive coronary artery disease (e.g.,
70% coronary artery obstruction or a positive stress test).
troke required documented focal neurological deficit last-
ng 24 h or until death, or if 24 h, there was a clinically
elevant lesion on brain imaging. Patients with focal neu-
ological deficits secondary to brain trauma, tumor, infec-
ion, or other nonvascular cause were excluded. Definite and
robable HF required clinical symptoms (e.g., shortness of
reath) or signs (e.g., edema), because asymptomatic disease
as not an end point. Probable HF further required a
hysician diagnosis of HF and medical treatment for HF.
efinite HF also required: 1) pulmonary edema/congestion
y chest radiograph; and/or 2) dilated ventricle or poor LV
unction by echocardiography or ventriculography, or evi-
ence of LV diastolic dysfunction.
tatistical methods. Unadjusted Cox proportional hazards
odels were first calculated for each end point (CHD
vents, stroke, HF) for LV mass and end-diastolic volume
eparately as continuous variables (per 10% increment) and
hen for LV mass and end-diastolic volume jointly in the
ame model to assess the role of LV geometry. Probable and
efinite HF and CHD events were considered in the
nalysis. All stroke events were definite. In additional
odels, the ratio of LV mass/volume was included both
ith and without adjustment for body size. In all instances,
here were only minor differences in the fit between these
odels, and for simplicity we only show the results for the
atio of unadjusted LV mass/volume. Then age, sex, eth-
icity, diabetes (diabetic, impaired fasting glucose, normal), 2igarette smoking (present, former, never), total cholesterol,
igh-density lipoprotein cholesterol, use of antihypertensive
r lipid-lowering medication, and systolic and diastolic
lood pressure were added to the models.
These analyses were repeated for incident CHD and
troke using quartiles of LV mass/volume. For incident HF,
n which body size-adjusted LV mass was the best predictor
f risk, instead of quartiles, the intervals were constructed to
isplay the nonlinearity in risk that was evident from
onlinear modeling (results not shown) of the risk in the
ox models. Kaplan-Meier cumulative event rate plots were
alculated for the above discrete intervals of the LV mea-
ures. Rates in 100 person-years are shown for descriptive
urposes for the quartiles of each LV measure.
All analyses were performed using Stata 10.0 for Win-
ows (Stata Corp., College Station, Texas). Values of p 
.05 are considered statistically significant and presented for
escriptive purposes. Confidence intervals (CIs) are ex-
ressed as 95% CIs.
esults
ubject characteristics. Of the 6,814 MESA study partic-
pants, 5,098 underwent cardiac MRI (75%) and 5,004
73%) had technically adequate data. Thirty-six participants
ad no follow-up information, leaving 4,968 participants in
he analysis. Compared with those not included in the
nalysis (n  1,846), those included were slightly younger
2.3 years younger), had lower systolic blood pressure (4.3
m Hg lower) and body mass index (2.2 U lower), were less
ikely to be African American (7.7% less), were more likely
o be Asian (4.8% more), and were less likely to have treated
ypertension (7.0% less) or diabetes (3.0% less). The mean
ge of the participants was 62 years (range 45 to 85 years);
2% of participants were female, 13% were Chinese-
merican, 26% were African American, 22% were His-
anic, and 39% were white.
ardiovascular events. There were 216 total events
hrough 5.2 years of follow-up (median 4 years). Angina
as most frequent (71 events), followed by HF (48 events),
yocardial infarction (45 events), stroke (39 events), and
HD death (13 events). Baseline characteristics of partici-
ants with and without cardiovascular events are shown in
able 1. Of CHD events, 100 were definite and 15 were
robable. Of HF events, 33 were definite and 15 were
robable. The participants who had cardiovascular events
ersus no events were more likely to be older at baseline (by
years), men (59% vs. 47%), diabetic (24% vs. 12%), and
urrent smokers (except for stroke events), and to use lipid
owering medication (28% vs. 15%) and hypertension med-
cation (57% vs. 35%), respectively. Participants in whom
F events developed versus no events were additionally
ore likely to be African American (35% vs. 26%), whereas
troke events versus no events were more likely in Hispanics
31% vs. 22%) and those with systolic hypertension (29% vs.
1%), respectively.
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December 16/23, 2008:2148–55 LV Mass and Geometry Predicting Events in the MESA Studyelationship of LV mass and geometry to incident
HD. The results of the unadjusted and adjusted Cox
roportional hazard models are shown in Table 2 for
ncident CHD events. After adjustment for risk factors,
ody size-adjusted LV mass, and end-diastolic volume
onsidered separately were not significant predictors of
Baseline Characteristics of the MESA Study CoP rticipants With and Without Selected Cardiov
Table 1 Baseline Characteristics of the MESParticipants With and Without Sele
Characteristic No Events (n  4,80
Age, yrs 61 (10)
Sex, n (%)
Women 2,549 (53)
Men 2,252 (47)
Ethnicity, n (%)
White 1,878 (39)
Chinese 633 (13)
African American 1,235 (26)
Hispanic 1,055 (22)
Cigarette smoking, n (%)
Never 2,491 (52)
Former 1,702 (36)
Current 595 (12)
Body mass index, kg/m2 28 (5)
Diabetes classification, n (%)
Normal 2,921 (61)
IFG 1,274 (27)
Diabetes 594 (12)
Hypertension medication, n (%)
No 3,140 (65)
Yes 1,658 (35)
Systolic blood pressure, mm Hg 125 (21)
Diastolic blood pressure, mm Hg 72 (10)
Lipid-lowering medication, n (%)
No 4,058 (85)
Yes 740 (15)
Total cholesterol, mg/dl 194 (35)
HDL cholesterol, mg/dl 51 (15)
For continuous variables, mean values ( SDs) are shown. *Fourteen
CHD  coronary heart disease; HDL  high-density lipoprotein; HF
The Relationship of LV End-Diastolic Volume and
Table 2 The Relationship of LV End-Diastolic
Model
Una
HR (95% CI)
LV mass† (per 10%) 1.1 (1.0–1.2)
LV volume† (per 10%) 0.9 (0.8–0.9)
LV mass/LV volume (g/ml) 5.5 (3.3–9.1)
LV mass/LV volume in quartiles
1st quartile (0.51–1.0) 1.0 (reference)
2nd quartile (1.0–1.13) 2.0 (1.0–4.0)
3rd quartile (1.13–1.29) 2.0 (1.0–4.1)
4th quartile (1.29–2.89) 5.3 (2.9–10.0)
*Adjusted for the following risk factors: age, sex, race, cigarette smoki
medication, systolic blood pressure, diastolic blood pressure, use of antihype
CHD  coronary heart disease; CI  confidence interval; HR  hazard ratiHD events. In combination, a greater LV mass/volume
atio was positively associated with incident CHD (hazard
atio (HR) for incident CHD: 2.1 per g/ml, p  0.02). The
V mass/volume ratio model had a similar fit to the model
hat included both body size-adjusted LV mass and end-
iastolic volume (not shown). A similar conclusion was
orlar Events
udy Cohort for
Cardiovascular Events
CHD (n  115)* Stroke (n  39) HF (n  48)
66 (9) 71 (8) 68 (9)
30 (26) 22 (56) 15 (31)
85 (74) 17 (44) 33 (69)
51 (44) 17 (44) 16 (33)
14 (12) 5 (13) 4 (8)
26 (22) 5 (13) 17 (35)
24 (21) 12 (31) 11 (23)
39 (34) 21 (54) 13 (28)
52 (45) 12 (31) 21 (45)
24 (21) 6 (15) 13 (28)
28 (5) 29 (4) 30 (6)
49 (43) 15 (39) 16 (33)
35 (30) 11 (29) 15 (31)
31 (27) 12 (32) 17 (35)
56 (49) 14 (36) 16 (33)
59 (51) 25 (64) 32 (67)
135 (23) 149 (29) 137 (20)
74 (11) 77 (14) 74 (11)
77 (67) 31 (79) 36 (75)
38 (33) 8 (21) 12 (25)
197 (38) 200 (38) 195 (37)
47 (15) 50 (12) 50 (15)
ants had 2 CHD events.
t failure; IFG  impaired fasting glucose.
s to CHD Events
me and Mass to CHD Events
Cox Models for Incident CHD
d Adjusted*
p Value HR (95% CI) p Value
0.05 1.0 (0.9–1.1) 0.39
0.002 0.9 (0.8–1.0) 0.09
0.0001 2.1 (1.1–4.1) 0.02
1.0 (reference)
0.05 1.5 (0.7–3.0) 0.30
0.05 1.3 (0.6–2.6) 0.63
0.0001 2.3 (1.2–4.4) 0.01
l cholesterol, high-density lipoprotein cholesterol, use of lipid-loweringhort fascu
A St
cted
1)Mas
Volu
djuste
ng, tota
rtensive drugs, and diabetes. †Adjusted for body size.
o; LV  left ventricular.
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LV Mass and Geometry Predicting Events in the MESA Study December 16/23, 2008:2148–55eached for a model based on quartiles of LV mass/volume
HR: 2.3 per g/ml for the upper quartile compared with the
rst quartile, p  0.01) (Fig. 1).
elationship of LV mass and geometry size to incident
troke. After adjustment for risk factors and in separate
odels, body size-adjusted LV mass but not LV end-
iastolic volume was positively associated with incident
troke (LV mass, HR: 1.2 per 10% increment, p  0.01)
Table 3). In the adjusted model, a greater LV mass/volume
atio was positively associated with stroke events (HR: 4.2
er g/ml, p 0.005). The LV mass/volume ratio model had
similar fit to a model that included both body size-
djusted LV mass and end-diastolic volume (not shown).
ith increasing LV mass/volume ratio, the number of
troke events increased in the adjusted model (highest
uartile vs. lowest quartile, HR: 11.1, p  0.02) (Fig. 2).
elationship of LV mass and geometry to incident
F. As shown in Table 4, in separate models both body
ize-adjusted LV mass and end-diastolic volume were pos-
tively associated with incident HF before and after adjust-
Figure 1 Cumulative Event Rates for CHD
Events by Quartiles of Left Ventricular Mass/Volume
CHD  coronary heart disease.
The Relationship of LV End-Diastolic Volume and
Table 3 The Relationship of LV End-Diastolic
Model
Una
HR (95% CI)
LV mass† (per 10%) 1.2 (1.1–1.4)
LV volume† (per 10%) 0.9 (0.7–1.1)
LV mass/LV volume (g/ml) 7.8 (3.6–17.3)
LV mass/LV volume in quartiles
1st quartile (0.51–1.0) 1.0 (reference)
2nd quartile (1.0–1.13) 6.0 (0.7–50.2)
3rd quartile (1.13–1.29) 10.2 (1.3–80.1)
4th quartile (1.29–2.89) 23.0 (3.1–170.5)
*Adjusted for the following risk factors: age, sex, race, cigarette smoki
medication, systolic blood pressure, diastolic blood pressure, use of antihype
Abbreviations as in Table 2.ent for risk factors (after adjustment, LV mass, HR: 1.4
er 10% increment, p  0.0001; LV volume, HR: 1.3 per
0% increment, p  0.0001). However, unlike incident
HD or stoke, incident HF in the fully adjusted models
as not significantly associated with LV mass/volume ratio
Table 4) (p  0.11). Thus, body size-adjusted LV mass
lone was the best measure of heart size to predict incident
F. Inclusion of LV ejection fraction in a model with LV
ass showed little change in the adjusted HRs or model fit.
Because only 1 HF event occurred in the reference group
1st quartile of LV mass), the HR ratio estimates with this
eference group were unstable. Most events occurred in
articipants with body size-adjusted LV mass 90% of
redicted based on height and weight. To examine the
radient of relative risk, 4 categories of LV mass index were
ompared: below the median (50th) percentile of LV mass
ndex (reference category), the 50th to 89th percentile, the
0th to 94th percentile, and 95th percentile of LV mass
ndex (as previously taken to be the definition of LVH
3,4,10,24]). The HR for participants with LVH (95th
s to Stroke Events
me and Mass to Stroke Events
Cox Models for Incident Stroke
d Adjusted*
p Value HR (95% CI) p Value
0.0001 1.2 (1.0–1.4) 0.01
0.16 0.9 (0.8–1.1) 0.51
0.0001 4.2 (1.5–11.2) 0.005
1.0 (reference)
0.10 4.1 (0.5–50.2) 0.20
0.03 6.8 (0.9–54.0) 0.07
0.003 11.1 (1.4–84.8) 0.02
l cholesterol, high-density lipoprotein cholesterol, use of lipid-lowering
Figure 2 Cumulative Event Rates for Stroke
Events by Quartiles of Left Ventricular Mass/VolumeMas
Volu
djuste
ng, tota
rtensive drugs, and diabetes. †Adjusted for body size.
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December 16/23, 2008:2148–55 LV Mass and Geometry Predicting Events in the MESA Studyercentile) versus those below the median for LV mass was
.6 (95% CI: 3.7 to 19.9, p  0.0001) (Fig. 3).
iscussion
he pathophysiologic changes in the size and function of
he heart in response to cardiovascular risk factors are
omplex, and increasingly accurate tools are now available to
xplore these relationships. The MESA study is the first
pidemiologic study that has used cardiac MRI in a large
ohort to evaluate incident cardiovascular events. There are
everal conclusions from this study: 1) In a diverse, multi-
thnic cohort, LVH confers a substantially elevated risk for
ncident HF, consistent with prior reports from predomi-
antly white or African-American cohorts. 2) Elevated LV
ass in most individuals was accommodated over the 4-year
eriod of follow-up, with only the top 5% of the cohort
howing increased risk for incident HF in adjusted models.
) Concentric remodeling (defined by elevated LV mass/
olume ratio), rather than elevated ventricular mass, was
The Relationship of LV End-Diastolic Volume and
Table 4 The Relationship of LV End-Diastolic
Model
Una
HR (95% CI)
LV mass† (per 10%) 1.4 (1.3–1.5)
LV volume† (per 10%) 1.3 (1.2–1.5)
LV mass/LV volume (g/ml) 7.4 (3.6–15.4)
LV mass† in intervals
50th percentile 1.0 (reference)
50th to 90th percentile 1.7 (0.8–3.7)
90th to 95th percentile 2.7 (0.6–12.3)
95th percentile 13.0 (6.1–27.7)
*Adjusted for the following risk factors: age, sex, race, cigarette smoki
medication, systolic blood pressure, diastolic blood pressure, use of a
Abbreviations as in Table 2.
Figure 3 Cumulative Event Rates for HF Events by Intervals
of Left Ventricular Mass (Body Size-Adjusted)
HF  heart failure.vredictive of incident non-HF cardiovascular events, specif-
cally stroke and CHD.
Data from the Framingham study has previously linked
VH detected by ECG to CHD (myocardial infarction,
ngina, sudden death) (1). Electrocardiogram-defined LVH
ad a 3-fold risk of developing clinically apparent CHD
including HF) compared with the group without LVH. In
ther observational studies, the relative risk of ECG-
efined LVH for incident HF only was 1.4 to 2.9 (3,5,6).
n ECG is a relatively low-cost method of detecting LVH
3,40,41), but the sensitivity of ECG for LVH is only 6% to
0% (3,41). Using echocardiography, the reported relative
isk of LVH for incident HF in previous observational
tudies was 1.6 to 3.4 (3,4,7).
For LV mass 95th percentile compared with the
eference group of 50% percentile, the adjusted HR for
F in the MESA study population was 8.6 (95% CI: 3.9 to
9.9) using MRI to measure heart size. The greater risk
onferred by LVH in this study compared with other
ohorts is notable. This greater risk may be explained by
emographic differences between the cohorts, different ap-
roaches to statistical assessment, and/or different methods
f heart size assessment (MRI vs. echocardiography or
CG). The high accuracy and reproducibility of cardiac
RI (standard errors of about 5% [32,42,43] compared
ith 20% for echocardiography [44] in single-center stud-
es) should facilitate risk estimates for short-term studies
hat by nature will entail fewer events. It is notable that LV
ass 95th percentile did not predict incident HF events
ver the 4-year period of follow-up in a cohort that was
symptomatic at baseline.
The relative role of LVH versus concentric remodeling
ssociated with cardiovascular events has been unclear.
oren et al. (22) originally reported a cardiovascular event
ate of 4.2 per 100 patient-years when concentric remodel-
ng was present, versus 1.8 per 100 patient years when there
as normal LV geometry. Similar results were identified in
ther studies (21,24,26,27), but no additional predictive
s to HF Events
me and Mass to HF Events
Cox Models for Incident HF
d Adjusted*
p Value HR (95% CI) p Value
0.0001 1.4 (1.2–1.5) 0.0001
0.0001 1.3 (1.2–1.5) 0.0001
0.0001 2.3 (0.8–6.1) 0.11
1.0 (reference)
0.21 1.6 (0.7–3.6) 0.23
0.20 2.4 (0.5–11.1) 0.27
0.0001 8.6 (3.7–19.9) 0.0001
l cholesterol, high-density lipoprotein cholesterol, use of lipid-lowering
rtensive drugs, and diabetes. †Adjusted for body size.Mas
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ng, totaalue for concentric hypertrophy beyond LV mass was
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ubjects studied by Verdecchia et al. (28). In general, prior
tudies have combined types of cardiovascular events to
xamine the relationship to LV mass or geometry. The
esults of this study show that stroke and CHD events were
etter predicted by elevated LV geometry, whereas HF
vents were driven primarily by LV mass alone. Although
ur results do not indicate causality, potential mechanisms
elating LV remodeling to abnormal arterial structure and
unction (45) and to stroke and CHD (46) have been
reviously described.
Reliable evaluation of the relationship of ethnicity in
elationship to LV mass and cardiovascular events will
equire additional follow-up and/or larger sample sizes. The
eneral applicability of our results may be limited by
election and survivor biases. Because MESA study partic-
pants had no known cardiovascular disease at baseline, the
lder individuals undergoing MRI in this cohort represent a
articularly healthy sample of the population at large. The
echanisms by which cardiovascular events result from
hanges in heart size are not elucidated by these observa-
ional data. At the time of data collection, only the fast-
radient echocardiographic MRI pulse sequence was avail-
ble at all of the field centers; the steady-state free-
recession sequence has since been developed for cardiac
RI, and this sequence shows better reproducibility for
ardiac mass and volume measurement. As indicated in the
ethods section, we did not include the papillary muscle
ass as part of the LV mass. The papillary muscle mass is
irectly related to LV mass over a wide range of values. The
V mass methods that include papillary muscles would thus
e somewhat larger and mass/volume ratios smaller than we
ave reported. The diagnosis of HF is not as definitive as
ther cardiovascular events such as stroke or myocardial
nfarction. Therefore, we required that participants be
ymptomatic with physician-diagnosed HF documented
n medical records that were adjudicated by physician
eviewers.
onclusions
n an ethnically diverse population free of symptomatic car-
iovascular disease at baseline, the end-diastolic volume and
ass of the LV determined by MRI were strongly associated
ith cardiovascular events. The association between stroke and
HD may be mediated through concentric ventricular remod-
ling, whereas incident HF was most closely associated with
ery high levels of LV mass.
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